Current research of Zevalin and Bexxar in the field of radioimmunotherapy / 复旦学报(医学版)
Fudan University Journal of Medical Sciences
;
(6): 786-788, 2009.
Artículo
en Chino
| WPRIM
| ID: wpr-405678
ABSTRACT
Radioimmunotherapy using monoclonal antibodies incorporated with radionuclide has been showed to be an effective agent for refractory non-Hodgkin's lymphoma (NHL). Many anti-CD20 antibodies labeled with radionuclide, such as 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab tiuxetan (Bexxar), have been reported to be effective for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed NHL. This review summarizes the current advance in clinical trials and studies of Zevalin and Bexxar for the treatment of NHL patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Fudan University Journal of Medical Sciences
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS